Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 14:19:749-752.
doi: 10.2147/COPD.S434011. eCollection 2024.

Severe COPD: Multidisciplinary Consultation to Get the Right Care at the Right Place

Pieter-Paul Hekking  1 , Monique van Meggelen  1 , W Johan Lie  2 , Rogier Arnaud Sebastiaan Hoek  3   4 , Dirk van Ranst  5 , Stephan Cornelis Johan van der Kleij  6 , Leonard Seghers  4 , Jasper Kappen  1   7 , Gert-Jan Braunstahl  1   8 , Johannes In 't Veen  1 ; Severe Asthma & COPD Network South West Netherlands
Affiliations

Severe COPD: Multidisciplinary Consultation to Get the Right Care at the Right Place

Pieter-Paul Hekking et al. Int J Chron Obstruct Pulmon Dis. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Dr Gert-Jan Braunstahl reports grants and/or personal fees from GSK, Sanofi, AstraZeneca, ALKAbello, outside the submitted work. Dr Johannes In ‘t Veen reports Unrestricted grant to institution from Teva, Astra Zeneca, Chiesi; Speaker Bureau for Sanofi, Chiesi, GSK, Astra Zeneca, Health Investment, StichtingRoLeX. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Former (A) and new (1–3) severe COPD care pathways resulting from organizing referrals via a multidisciplinary consultation with experts in different targeted treatments. (B) targeted treatments and advices, divided by the initial question from the referring physician and the advice from the expert panel. (A) shows the pre MDC pathway, in which pulmonologist directly referred to a specialized center, resulting in a single advice for one specific treatment. Pathways 1, 2 and 3 are the novel routes after patients have been presented to the MDC. 1) The referring physician is advised to initiate a certain treatment or additive diagnostics in their own center, 2) referral physicians are advised to refer patients to one of the specialized centers for further treatment, or 3) patients are referred for a tertiary assessment to optimize diagnosis and identify treatable traits (B).
See this image and copyright information in PMC

References

    1. Justin T, Suzanne M, Brent C, et al. Richard Beasley External validity of randomized controlled trials in COPD. Respir Med. 2007;101:1313–1320. doi:10.1016/j.rmed.2006.10.011 - DOI - PubMed
    1. van Dijk M, Gan CT, Koster TD, et al. Treatment of severe stable COPD: the multidimensional approach of treatable traits. ERJ Open Res. 2020;6:00322–2019. doi:10.1183/23120541.00322-2019 - DOI - PMC - PubMed
    1. Bhatt SP, Rabe KF, Hanania NA, et al. BOREAS investigators. Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts. N Engl J Med. 2023;389:205–214. doi:10.1056/NEJMoa2303951 - DOI - PubMed
    1. Kuzma AM, Meli Y, Meldrum C, et al. Multidisciplinary care of the patient with chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2008;5:567–571. doi:10.1513/pats.200708-125ET - DOI - PMC - PubMed
    1. Hurst JR, Winders T, Worth H, et al. A patient charter for chronic obstructive pulmonary disease. Adv Ther. 2021;38:11–23. doi:10.1007/s12325-020-01577-7 - DOI - PMC - PubMed

Publication types

MeSH terms